Moraru R, Valle-Argos B, Minton A, Buermann L, Pan S, Wales T
J Med Chem. 2024; 67(16):13572-13593.
PMID: 39119945
PMC: 11345841.
DOI: 10.1021/acs.jmedchem.3c01927.
Alu A, Lei H, Han X, Wei Y, Wei X
J Hematol Oncol. 2022; 15(1):138.
PMID: 36183125
PMC: 9526392.
DOI: 10.1186/s13045-022-01353-w.
Murugesan R, Sureshkumar R, Radhakrishnan A, Jupudi S, Chennu M
Adv Pharm Bull. 2022; 12(3):509-514.
PMID: 35935048
PMC: 9348525.
DOI: 10.34172/apb.2022.053.
Chawla S, Jindal A, Arora K, Tyagi R, Dhaliwal M, Rawat A
Clin Rev Allergy Immunol. 2022; 65(1):31-42.
PMID: 35708830
PMC: 9201264.
DOI: 10.1007/s12016-022-08949-7.
Li X, Zeng Q, Wang S, Li M, Chen X, Huang Y
Front Immunol. 2021; 12:779560.
PMID: 34745151
PMC: 8569388.
DOI: 10.3389/fimmu.2021.779560.
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Estupinan H, Wang Q, Berglof A, Schaafsma G, Shi Y, Zhou L
Leukemia. 2021; 35(5):1317-1329.
PMID: 33526860
PMC: 8102192.
DOI: 10.1038/s41375-021-01123-6.
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.
Hamasy A, Wang Q, Blomberg K, Mohammad D, Yu L, Vihinen M
Leukemia. 2016; 31(1):177-185.
PMID: 27282255
PMC: 5220130.
DOI: 10.1038/leu.2016.153.
Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.
Kokabee L, Wang X, Sevinsky C, Wang W, Cheu L, Chittur S
Cancer Biol Ther. 2015; 16(11):1604-15.
PMID: 26383180
PMC: 4846115.
DOI: 10.1080/15384047.2015.1078023.
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.
Bestas B, Moreno P, Blomberg K, Mohammad D, Saleh A, Sutlu T
J Clin Invest. 2014; 124(9):4067-81.
PMID: 25105368
PMC: 4151202.
DOI: 10.1172/JCI76175.
BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
Spaargaren M, de Rooij M, Kater A, Eldering E
Oncogene. 2014; 34(19):2426-36.
PMID: 24954503
DOI: 10.1038/onc.2014.181.
B-lymphocyte tolerance and effector function in immunity and autoimmunity.
Khan W, Wright J, Kleiman E, Boucher J, Castro I, Clark E
Immunol Res. 2013; 57(1-3):335-53.
PMID: 24293007
DOI: 10.1007/s12026-013-8466-z.
The genetic theory of infectious diseases: a brief history and selected illustrations.
Casanova J, Abel L
Annu Rev Genomics Hum Genet. 2013; 14:215-43.
PMID: 23724903
PMC: 4980761.
DOI: 10.1146/annurev-genom-091212-153448.
Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORγt and Ahr that leads to IL-17 production by activated B cells.
Bermejo D, Jackson S, Gorosito-Serran M, Acosta-Rodriguez E, Amezcua-Vesely M, Sather B
Nat Immunol. 2013; 14(5):514-22.
PMID: 23563688
PMC: 3631452.
DOI: 10.1038/ni.2569.
Differential impact of Toll-like receptor signaling on distinct B cell subpopulations.
Meyer-Bahlburg A, Rawlings D
Front Biosci (Landmark Ed). 2011; 17(4):1499-516.
PMID: 22201817
PMC: 3601656.
DOI: 10.2741/4000.
Clinical consequences of defects in B-cell development.
Vale A, Schroeder Jr H
J Allergy Clin Immunol. 2010; 125(4):778-87.
PMID: 20371392
PMC: 3653433.
DOI: 10.1016/j.jaci.2010.02.018.
Hypoxia-induced mitogenic factor/FIZZ1 induces intracellular calcium release through the PLC-IP(3) pathway.
Fan C, Su Q, Li Y, Liang L, Angelini D, Guggino W
Am J Physiol Lung Cell Mol Physiol. 2009; 297(2):L263-70.
PMID: 19429774
PMC: 2742792.
DOI: 10.1152/ajplung.90416.2008.
B lymphocytes: how they develop and function.
Lebien T, Tedder T
Blood. 2008; 112(5):1570-80.
PMID: 18725575
PMC: 2518873.
DOI: 10.1182/blood-2008-02-078071.
Myc stimulates B lymphocyte differentiation and amplifies calcium signaling.
Habib T, Park H, Tsang M, Moreno de Alboran I, Nicks A, Wilson L
J Cell Biol. 2007; 179(4):717-31.
PMID: 17998397
PMC: 2080907.
DOI: 10.1083/jcb.200704173.
Coupling Ca2+ store release to Icrac channel activation in B lymphocytes requires the activity of Lyn and Syk kinases.
Chung S, Limnander A, Kurosaki T, Weiss A, Korenbrot J
J Cell Biol. 2007; 177(2):317-28.
PMID: 17452533
PMC: 2064139.
DOI: 10.1083/jcb.200702050.
Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright.
Rajaiya J, Hatfield M, Nixon J, Rawlings D, Webb C
Mol Cell Biol. 2005; 25(6):2073-84.
PMID: 15743806
PMC: 1061591.
DOI: 10.1128/MCB.25.6.2073-2084.2005.